Search

everythinglearnresearchcommunity

for

Search:↓

Some users of RU-58841 report cardiovascular symptoms like heart palpitations and chest tightness, which may be linked to its metabolites causing lung disease. The safety of RU-58841 is uncertain due to lack of long-term data and concerns about product purity, especially from gray market sources.

The conversation discusses adding either RU58841 or pyrilutamide to a hair loss treatment regimen that already includes oral dutasteride and oral minoxidil. RU58841 is considered the stronger anti-androgen but may have more side effects.

A 23-year-old male is experiencing diffuse hair loss and miniaturization, possibly due to high IGE levels after using tofacitinib. He seeks advice and has not yet consulted a dermatologist.

KX-826 is undergoing Phase III trials in China as a potential treatment for male pattern baldness, with some users considering it as an alternative or addition to finasteride and dutasteride. Opinions on its effectiveness vary, with some users reporting positive results and others finding it expensive and ineffective.

A user, 18, is considering switching from topical finasteride (0.025%) and minoxidil to dutasteride due to continued hair shedding. Other users shared their experiences with dutasteride, noting potential benefits and risks, including reduced sperm count.

Pyrilutamide/KX-826 is being considered as a potential treatment for female androgenetic alopecia (AGA), but its high cost and limited data on effectiveness are concerns. Kintor markets it for both men and women.

A user's regimen to help with their diffuse thinning, which includes taking Pyrilutamide BID, 1mg finasteride daily, 2.5mg oral minoxidil daily, topical minoxidil since August 2021, LLLT every two days, topical fin, progesterone, melatonin, minoxidil (started one week ago), pumpkin seed oil and not dermarolling; other commenters suggested Nizoral for dandruff control and caution when using pre-mixed products with Pyrilutamide.

A potential non-invasive topical treatment targeting the WNT Signaling Pathway for hair regeneration is being researched, with positive results on human hair follicle cells. Current effective treatments for hair loss include Minoxidil, finasteride, and hair transplantation.

PP405 shows promise for hair regrowth, with new hairs observed in 66% of patients in just 27 days. The discussion also mentions Minoxidil, finasteride, and RU58841 as potential treatments.

The user experienced hair regrowth over a year using minoxidil and inconsistent finasteride, along with a diet including natural DHT-blocking foods. They are pleased with the progress but aim for more consistency.

A 25-year-old male with normal hormone levels is considering starting finasteride and minoxidil for hair loss but is concerned about high estradiol levels and potential side effects. Responses vary, with some suggesting blood tests before starting treatment and others emphasizing individual tolerance and the importance of consulting a doctor.

A 15-year-old experiencing severe diffuse thinning plans to use minoxidil, dermarolling, and possibly ketoconazole, with hopes to later incorporate finasteride. Concerns about starting finasteride too young and the need for a dermatologist consultation are discussed.

A 28-year-old man had a hair transplant in India, choosing not to start finasteride due to past side effects with other medications but will use minoxidil for six months post-surgery. He researched and selected a clinic in Mumbai with a high reputation, underwent a 9-hour procedure for $965, and is optimistic about the results.

A 15-year-old is concerned about hair loss, possibly at Norwood 2 or 3, and is using shampoos and conditioners recommended by a trichologist. Suggestions include considering topical minoxidil and consulting a doctor about topical anti-DHT treatments like finasteride or RU58841, but avoiding 5-alpha-reductase inhibitors at this age.

33 y/o male used topical fin/min and dermaroll biweekly, resulting in increased hair density and significant regrowth. He got the solution from Hims and also used a DermaPen for microneedling.

30 y/o male started balding at 22, began treatment at 29 using oral dut, oral min, derma rolling, nizoral shampoo, and considering low level light therapy. Plans to monitor progress for 1-2 years and may get hair transplant or use hair system if needed.

A 29-year-old female is experiencing severe hair loss and bald patches, seeking advice on shampoos, conditioners, hair masks, or topical medications. A user suggests starting an oral supplement.

A 21-year-old experienced erectile dysfunction after using finasteride and consuming multiple drugs, including MDMA, LSD, and weed. He plans to quit finasteride and weed, improve his habits, and consider alternative treatments like mesotherapy with dutasteride.

The user experienced significant hair shedding after long-term use of finasteride and dutasteride and is now considering trying RU58841 as a last resort. They have checked health factors and suspect stress and poor sleep may contribute to the shedding, but they are determined to try RU58841 to see if it helps with androgenetic alopecia.

Female (37) experiencing hair loss for 5 years, tried max dose of spiro and oral + topical minox without success. Discovered low cortisol and low DHEA levels, seeking functional medicine practitioner for help.

A 26-year-old male has been using Redensyl for nearly two months without progress and recently switched to minoxidil. He is also taking multivitamins with biotin and using ciclopirox shampoo for dandruff.

The user is experiencing hair loss and has been using RU58841 but is considering pyrilutamide and minoxidil, avoiding finasteride due to side effects. Another user suggests finasteride or dutasteride as essential, possibly in topical form, while dismissing saw palmetto as ineffective.

Clascoterone is a topical treatment for androgenetic alopecia, showing modest to moderate hair regrowth, and may be available by 2027-2028. It is considered safer than finasteride, with discussions on its effectiveness compared to RU58841 and pyrilutamide.

RU58841 was used by some for hair loss, but concerns about side effects like gynecomastia and safety were raised. Alternatives like finasteride, minoxidil, pyrilutamide, and alfatradiol were discussed, with some users reporting better experiences with these treatments.

A 23-year-old is using 0.25mg Finasteride for hair loss and experiencing increased shedding after initial reduction. Advice given is to wait longer for results, as hair cycles take time to adjust, and consider increasing the dose if no improvement occurs in a few months.

An 18-year-old noticed significant hairline recession and is concerned about further hair loss. They plan to improve their lifestyle and are advised to use finasteride and minoxidil and consult a dermatologist.

GHK-Cu is a potent inhibitor of the type 1 5-alpha reductase enzyme in hair follicles, which may reduce hair loss without the side effects associated with type 2 5-alpha reductase inhibitors. The user previously experienced side effects with 5-alpha reductase inhibitors and is considering GHK-Cu as an alternative.

A user experienced severe chest pains and shortness of breath after using RU58841 for hair loss and was advised by a doctor that blocking androgens can weaken the heart. They decided to continue with finasteride, minoxidil, and a hair transplant instead.

The user has been using finasteride and minoxidil for hair loss but is experiencing thinning at the crown and is considering a hair transplant. They are seeking advice on other treatments to try before proceeding with a transplant and how to find a reputable doctor.

A 28-year-old man with hair loss is seeing regrowth in his temple area after 2 months of treatment with Dutasteride, a 1.5mm Dermaroller, topical Minoxidil, and Biotin supplements. He also notes an unexpected positive side effect of Dutasteride clearing up his light facial acne.